Psoriasis Vulgaris
Conditions
Brief summary
The objective is to compare the initial skin inflammatory transcriptomic profile of psoriatic patient responder to Adalimumab therapy (defined as the achievement of a Psoriasis Area and Severity Index 75 response at 16 weeks) with the transcriptomic profile of patient non-responder to Adalimumab therapy (defined as the non-achievement of a Psoriasis Area and Severity Index 50 response at 16 weeks) to identify differentially expressed genes in order to define predictive markers of response to the treatment.
Interventions
DIAGNOSTIC_TESTcutaneous
SKIN BIOPSY
Sponsors
Poitiers University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Chronic plaque psoriasis involving at least 10% of body surface area, with a PASI score \>10, * Negative pregnancy test for women of childbearing potential, and use of an effective method of contraception, * Pretreatment assessment to identify contraindications to anti-tumor necrosis factor-alpha therapy (chest x-ray and Intradermal reaction (detection of latent tuberculosis), * Anti-tumor necrosis factor-alpha treatment with adalimumab has been prescribed
Exclusion criteria
* Classical
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline messenger ribonucleic acid expression at 16 weeks of treatment | From baseline to 16 weeks treatment | messenger ribonucleic acid expression assessed by quantitative reverse transcription-polymerase chain reaction |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline drug and anti-drug concentrations at 16 weeks of treatment | From baseline to 16 weeks treatment | assessed by enzyme-linked-immunoassay |
Countries
France
Outcome results
None listed